Evidence map›Paper›PMID 41906224›Full record

ReviewBioFactors (Oxford, England)

Is There an Ace Up One's Sleeve in the Preanalytical Phase of the Circulating Tumor DNA Analysis?

Juscelino Carvalho de Azevedo Junior, Douglas Rafael da Cruz Carneiro, Fernanda Jardim da Silva, Ana Beatriz Lima Belicha, Anna Carolina Lima Rodrigues, Williams Fernandes Barra, Alessandro Leal, Danielle Queiroz Calcagno

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in BioFactors (Oxford, England). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Juscelino Carvalho de Azevedo JuniorNúcleo de Pesquisas em Oncologia, Universidade Federal do Pará, Belém, Pará, Brazil.ORCID https://orcid.org/0000-0001-8770-9490
Douglas Rafael da Cruz CarneiroPrograma de Residência Multiprofissional em Saúde (Oncologia), Hospital Universitário João de Barros Barreto, Universidade Federal do Pará, Belém, Pará, Brazil.
Fernanda Jardim da SilvaNúcleo de Pesquisas em Oncologia, Universidade Federal do Pará, Belém, Pará, Brazil.
Ana Beatriz Lima BelichaNúcleo de Pesquisas em Oncologia, Universidade Federal do Pará, Belém, Pará, Brazil.
Anna Carolina Lima RodriguesPrograma de Residência Multiprofissional em Saúde (Oncologia), Hospital Universitário João de Barros Barreto, Universidade Federal do Pará, Belém, Pará, Brazil.
Williams Fernandes BarraInstituto de Ciências da Saúde, Universidade Federal do Pará, Belém, Pará, Brazil.
Alessandro LealThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Danielle Queiroz CalcagnoNúcleo de Pesquisas em Oncologia, Universidade Federal do Pará, Belém, Pará, Brazil.ORCID https://orcid.org/0000-0002-4429-2573

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico 315643/2023-4Conselho Nacional de Desenvolvimento Científico e Tecnológico 409332/2021-6Coordenação de Aperfeiçoamento de Pessoal de Nível SuperiorMinistério da EducaçãoUniversidade Federal do Pará
6 · The paper itself

Abstract

Circulating tumor DNA (ctDNA) analysis has emerged as a pivotal minimally invasive tool for early detection, monitoring, and treatment stratification in cancer patients. However, the accuracy and reliability of ctDNA assays are profoundly influenced by preanalytical variables. This review discusses the impact of biological features (circadian rhythm, age, and sex), lifestyle factors (diet, smoking, and physical activity), as well as technical aspects such as hemolysis, leukocyte lysis, and delayed plasma separation on ctDNA integrity and concentration. Fluctuations in ctDNA levels driven by these factors highlight the need for clear guidelines regarding precollection timing, dietary restrictions, and sample processing. Furthermore, the adoption of harmonized protocols is essential to reduce variability and improve reproducibility across clinical and research settings.

Indexed as

Biomarkers, TumorCirculating Tumor DNANeoplasmsPre-Analytical PhaseHumansReproducibility of ResultsBiomarkers, TumorCirculating Tumor DNAcell deathliquid biopsypreanalytical variablesprecision medicinestandardization of preanalytical methodstumor biomarkers

Identifiers

PMID41906224
PMCPMC13033619

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.